Action About Unapproved Opioids Amended

August 2009
Critical Care Nurse;Aug2009, Vol. 29 Issue 4, p6
Academic Journal
The article reports on changes which the U.S. Food and Drug Administration made to recommendations on unapproved prescription opioids that it had made on March 30, 2009. The recommendations had asked drug manufacturers to stop the production and distribution of certain unapproved prescription opioids. As a result of the changes the administration will allow the continued marketing and distribution of one particular type of opioid, a high-concentrate morphine sulfate oral solution.


Related Articles

  • Genzyme's Scale-Up Issues for Lumizyme Still Not Resolved.  // BioPharm International;Apr2009, Vol. 22 Issue 4, p14 

    The article offers updates on the application of Genzyme Corp. to the U.S. Food and Drug Administration (FDA) to market its enzyme replacement therapy Lumizyme in the U.S. It notes the letter from the FDA which highlights the remaining qualifications which must be completed by Genzyme Corp....

  • FDA ROUNDUP: Roche Holding AG (Basel, Switzerland) won approval for its Actemra drug to treat rheumatoid arthritis.  // MondayMorning;1/18/2010, Vol. 18 Issue 2, p14 

    The article offers news briefs involving the U.S. Food and Drug Administration (FDA) in the pharmaceutical industry. FDA has approved the Actemra drug of Roche Holding AG to treat rheumatoid arthritis. Enforcement letters are issued by the FDA to Eli Lilly & Co., Amylin Pharmaceuticals Inc. and...

  • FDA promotion rules under scrutiny. Wechsler, Jill // Pharmaceutical Executive;Sep98, Vol. 18 Issue 9, DTC in D.C. p16 

    Scrutinizes the authority of Food and Drug Administration (FDA) to regulate how the pharmaceutical industry promote their products in the United States. Regulations regarding pharmaceutical marketing; Developments on the direct-to-consumer (DTC) broadcasting policy of FDA.

  • Last-minute rush brings spate of FDA drug approvals. Rodgers, Katie // Drug Topics;1/24/94, Vol. 138 Issue 2, p67 

    Reports on Food & Drug Administration's granting of marketing approvals for new drugs. Includes Genentech's market of DNase protein Pulmozyme for cystic fibrosis; Neurontin epilepsy treatment from Parke-Davis division of Warner-Lambert; Risperdal as a schizophrenia drug; Wyeth-Ayerst...

  • OPDP expands "Bad Ad" with CME. Iskowitz, Marc // Medical Marketing & Media;Dec2013, Vol. 48 Issue 12, p18 

    The article reports on the launch of course and case studies by the Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) as part of the Bad Ad program to raise awareness of misleading or false prescription drug promotion.

  • New rules for opioid prescribing.  // Critical Care Alert;Apr2009 Pharmacology, p2 

    The article reports on the restrictions imposed by the Food & Drug Administration (FDA) on the use of opioid drugs in the U.S.

  • DDMAC enforcement letters skyrocket. J. G. D. // Medical Marketing & Media;Nov2010, Vol. 45 Issue 11, p30 

    The article reports on the increasing number of letters sent by the U.S. Food and Drug Administration (FDA) that warn pharmaceutical marketers who violate agency advertising and promotion regulations.

  • As I See It. Thacker, Paul D. // Medical Marketing & Media;Jan2012, Vol. 47 Issue 1, p26 

    The article presents the author's views on the move of the pharmaceutical industry to pressure the U.S. Congress and the Food and Drug Administration (FDA) regarding the conflict-of-interest on safety rules.

  • So Little Time - So Much To Do. Auerbach, Michael // Pharmaceutical Processing;Jan2009, Vol. 24 Issue 1, p6 

    The article discusses the report published within this issue by John Avellanet on the business, regulatory and manufacturing issues that the U.S. Food and Drug Administration (FDA) will consider for the pharmaceutical industry in 2009.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics